543737-10-6

Basic information

• Product Name: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline
• Synonyms: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline;Isoquinoline, 4-(3-bromophenyl)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-
• CAS NO: 543737-10-6
• Molecular Formula: C₁₆H₁₄BrCl₂N
• Molecular Weight: 371.11
• Mol File: 543737-10-6.mol

Chemical Properties

• Boiling Point: 412.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.475±0.06 g/cm3(Predicted)
• PKA: 6.79±0.40(Predicted)
• CAS DataBase Reference: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline(543737-10-6)
• EPA Substance Registry System: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline(543737-10-6)

Safety Data

• Hazardous Substances Data: 543737-10-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline is used as a pharmacological agent for its dopamine receptor antagonistic properties, primarily targeting the dopamine D1 and D5 receptors. It is utilized in the development of treatments for various central nervous system disorders due to its potential antipsychotic effects.
Used in Research and Development:
In the field of medicinal chemistry and neuroscience, 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline serves as a subject of research for understanding its mechanism of action and exploring its therapeutic potential. It aids in advancing knowledge about the role of dopamine receptors in mental health conditions and the development of novel treatments.
Used in the Treatment of Schizophrenia:
4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline is considered for use as an antipsychotic medication, specifically for the management of schizophrenia. Its ability to modulate dopamine signaling is believed to help alleviate the symptoms associated with this mental disorder.
Used in the Management of Bipolar Disorder:
4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline is also being studied for its potential application in the treatment of bipolar disorder, where its receptor antagonistic activity may contribute to stabilizing mood swings and managing the associated psychotic features.

Upstream product

• 1234366-97-2 1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanol 

Downstream Products

• 1870821-29-6 (4S)-4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract